Omeros (NASDAQ:OMER) issued its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.04), Fidelity Earnings reports. The firm had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $3.07 million. During the same quarter in the prior year, the business earned ($0.16) EPS.
Shares of Omeros stock traded down $3.00 during trading on Friday, reaching $13.02. 5,656,225 shares of the company traded hands, compared to its average volume of 613,109. Omeros has a 1-year low of $8.36 and a 1-year high of $27.00. The company has a market capitalization of $793.47 million, a PE ratio of -16.48 and a beta of 3.79.
In related news, VP Marcia S. Kelbon sold 7,529 shares of the business’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $25.75, for a total transaction of $193,871.75. Following the transaction, the vice president now owns 227,645 shares in the company, valued at approximately $5,861,858.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.10% of the stock is owned by insiders.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Further Reading: Rule of 72
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.